P2.03a-034 RRM1 - A Prognostic Marker in Advanced NSCLC among Male Smokers Receiving Chemotherapy

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

BACKGROUND Customizing chemotherapy on the basis of chemosentitivity prediction may improve outcome in advanced bladder cancer patients. Since DNA damaging agents are the cornerstones of therapy, we hypothesized that levels of DNA repair genes could predict survival. PATIENTS AND METHODS Messenger RNA expression levels of excision repair cross complementing 1 (ERCC1), breast cancer 1 (BRCA1),...

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

PURPOSE Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. Unfortunately, less than half of the patients achieve the benefit from chemotherapy. Gemcitabine is an analog of deoxycytidine (pyrimidine antimetabolite) with ant...

Erythropoietin Receptor Activator) in anemic patients with advanced non- small cell lung cancer (NSCLC) receiving chemotherapy

[Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].

Gemcitabine in RRM1-negative Advanced Refractory Non-small Cell Lung Cancer (NSCLC): A Case Report Meiling ZHAO, Haihong YANG, Jianxing HE Department of Cardiothoracic Surgery, Guangzhou Institution of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, China; Graduate College of Southern Medical University, Guangzhou 510515, China Corresponding au...

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.

BACKGROUND Anti-vascular endothelial growth factor therapy (VEGF) is an important new treatment modality in oncology. We sought to determine the efficacy and safety of the humanized monoclonal anti-VEGF antibody, bevacizumab, and vinorelbine as treatment for refractory breast cancer and to explore the role of plasma VEGF as a predictor of treatment outcome. EXPERIMENTAL DESIGN Eligible patien...